SciClone Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2016. For the quarter, the company's total net revenues were $44,062,000 compared to $42,863,000 a year ago. Income from operations was $7,407,000 compared to $12,690,000 a year ago. Income before provision for income tax was $7,183,000 compared to $12,740,000 a year ago. Net income was $6,411,000 compared to $12,544,000 a year ago. Diluted net income per share was $0.12 compared to $0.24 a year ago. Non-GAAP net income was $10,733,000 compared to $15,548,000 a year ago. Non-GAAP diluted net income per share was $0.20 compared to $0.30 a year ago.

For the year, the company's total net revenues were $160,096,000 compared to $157,257,000 a year ago. Income from operations was $33,235,000 compared to $29,911,000 a year ago. Income before provision for income tax was $34,133,000 compared to $30,270,000 a year ago. Net income was $30,729,000 compared to $29,463,000 a year ago. Diluted net income per share was $0.58 compared to $0.56 a year ago. Non-GAAP net income was $43,836,000 compared to $52,230,000 a year ago. Non-GAAP diluted net income per share was $0.83 compared to $1.00 a year ago.

The company projects its 2017 revenue to be in the range between $170 and $175 million, driven by ZADAXIN revenues; and its non-GAAP diluted earnings per share to be in the range between $0.60 and $0.64.